Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy

por Beattie, David T., Pulido-Rios, M. Teresa, Shen, Fei, Ho, Melissa, Situ, Eva, Tsuruda, Pam R., Brassil, Patrick, Kleinschek, Melanie, Hegde, Sharath
Publicado 2017

Pharmacological properties of revefenacin (TD‐4208), a novel, nebulized long‐acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat,...

por Hegde, Sharath S., Pulido‐Rios, M. Teresa, Luttmann, Mark A., Foley, James J., Hunsberger, Gerald E., Steinfeld, Tod, Lee, TaeWeon, Ji, Yuhua, Mammen, Mathai M., Jasper, Jeffrey R.
Publicado 2018

Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme

por Sandborn, William J, Nguyen, Deanna D, Beattie, David T, Brassil, Patrick, Krey, Whitney, Woo, Jacky, Situ, Eva, Sana, Reuben, Sandvik, Erik, Pulido-Rios, M Teresa, Bhandari, Raj, Leighton, Jonathan A, Ganeshappa, Ravi, Boyle, David L, Abhyankar, Brihad, Kleinschek, Melanie A, Graham, Richard A, Panes, Julian
Publicado 2020